Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 202-874-0 | CAS number: 100-64-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Key value for chemical safety assessment
Skin sensitisation
Link to relevant study records
- Endpoint:
- skin sensitisation: in vivo (LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2008
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Study according to guideline, limited documentation
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay)
- Deviations:
- no
- GLP compliance:
- not specified
- Type of study:
- mouse local lymph node assay (LLNA)
- Species:
- mouse
- Strain:
- CBA
- Sex:
- female
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Source: Harlan (Horst, The Netherlands) or Scanbur (Sollentuna, Sveden)
- Age at study initiation: 8 weeks - Vehicle:
- acetone/olive oil (4:1 v/v)
- Concentration:
- 0, 0.1, 1, 5, 10 or 20%
- No. of animals per dose:
- 3-4
- Details on study design:
- - Quantitative criteria used to consider a positive response: EC3 < 0.1 extreme; >=0.1-<1: strong; >=1-<10 moderate;>=10-100: weak
TREATMENT PREPARATION AND ADMINISTRATION:
Mice received 25 μL of the test compound dissolved in vehicle on the dorsum of the ears daily for three consecutive days. Control animals were treated in the same way with vehicle. Mice were injected intravenously five days after the first treatment with 20 μCi of [3H]thymidine in 250 μL of phosphate-buffered saline. Five hours later, draining auricular lymph nodes were excised and pooled for each group. A single cell suspension of lymph node cells was prepared. The thymidine incorporation was measured by scintillation counting.
Results are expressed as mean dpm/lymph node for each experimental group and as stimulation index (SI), that is, test group/control group ratio. - Positive control substance(s):
- not specified
- Statistics:
- EC3 values (concentration required to induce a stimulation index (SI) of 3) were calculated with linear interpolation
- Positive control results:
- Other test substances produced SI up to 11.3 can therefore be considered as valid positive controls
- Parameter:
- SI
- Remarks on result:
- other: Conc. SI [% w/v) Control: - 0.1: 0.96 1: 0.90 5: 0.77 10: 1.17 20 0.84
- Parameter:
- other: disintegrations per minute (DPM)
- Remarks on result:
- other: Conc. dpm [% w/v) Control: 1081 0.1: 1036 1: 978 5: 828 10: 1260 20 906
- Interpretation of results:
- not sensitising
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- Under the conditions of this study the test substance was not sensitising
- Executive summary:
Female mice (3-4 per dose group) received the test item on the dorsum of the ears daily for three consecutive days in concentrations of 0, 0.1, 1, 5, 10 or 20% in acetone/olive oil (4:1) vehicle. Five days later the animals were injected i.v. with 20 µCi 3H-thymidine in 250 µL phosphate buffered saline. The auricular lymph nodes were excised 5 h later and pooled from each group. The prepared cell suspension (one per dose group) was measured by scintillation counting. Dpm/lymph nodes were determined and the stimulation index (SI) compared to controls as well as the effect concentration producing a 3 -fold increase in SI (EC3) were calculated. The test substance produced SI between 0.77 and 1.17, resulting in an EC3 > 20%. According to the evaluation score of the authors they described the test item as weak sensitiser. Based on the guideline scoring scheme (SI >=3: positive) it is not considered to be a sensitiser. No data are given for a positive control, but other test substances produced SI up to 11.3, what is considered to be a positive response, indicating the validity of the test.
Therefore under the conditions of this study the test substance was not sensitising
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (not sensitising)
- Additional information:
There is one LLNA assay available to assess the sensitising properties of CHO (guideline study, RL2). The test substance produced SI between 0.77 and 1.17, resulting in an EC3 > 20%. According to the evaluation score of the authors they described the test item as weak sensitiser. Based on the guideline scoring scheme (SI >=3: positive) it is not considered to be a sensitiser.
Migrated from Short description of key information:
A reliable local lymph node assay (LLNA) according to guideline revealed cyclohexanone oxime (CHO) as not sensitising.
Justification for selection of skin sensitisation endpoint:
only reliable study available (Klimisch 2)
Respiratory sensitisation
Endpoint conclusion
- Endpoint conclusion:
- no study available
Justification for classification or non-classification
Based on the findings of a guideline study CHO has not to be classified for sensitisation according to Regulation (EC) No 1272/2008 and Council Directive 67/548/EEC.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.